Holen Sie sich die Stockscreener-App
90.85
3.32%
-3.12
Handel nachbörslich:
90.90
0.05
+0.06%
Schlusskurs vom Vortag:
$93.97
Offen:
$92.88
24-Stunden-Volumen:
588.94K
Relative Volume:
0.55
Marktkapitalisierung:
$3.15B
Einnahmen:
$635.89M
Nettoeinkommen (Verlust:
$171.92M
KGV:
20.85
EPS:
4.357
Netto-Cashflow:
$151.36M
1W Leistung:
+1.35%
1M Leistung:
+23.66%
6M Leistung:
-32.33%
1J Leistung:
-25.46%
1-Tages-Spanne:
$90.64
$94.30
1-Wochen-Bereich:
$86.80
$94.99
52-Wochen-Spanne:
$60.10
$156.00
Transmedics Group Inc Stock (TMDX) Company Profile
Firmenname
Transmedics Group Inc
Sektor
Branche
Telefon
(978) 552-0900
Adresse
200 MINUTEMAN ROAD, ANDOVER, MA
Compare TMDX vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMDX
Transmedics Group Inc
|
90.85 | 3.26B | 635.89M | 171.92M | 151.36M | 4.357 |
ABT
Abbott Laboratories
|
114.14 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
327.70 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.30 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.37 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.83 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Transmedics Group Inc Stock (TMDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-23 | Hochstufung | Needham | Hold → Buy |
| 2025-10-13 | Eingeleitet | Jefferies | Buy |
| 2025-09-16 | Eingeleitet | Evercore ISI | Outperform |
| 2025-09-04 | Eingeleitet | Stifel | Hold |
| 2024-12-17 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-11-22 | Herabstufung | Needham | Buy → Hold |
| 2024-10-29 | Bestätigt | Needham | Buy |
| 2024-10-29 | Bestätigt | Oppenheimer | Outperform |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-21 | Eingeleitet | Needham | Buy |
| 2024-06-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-04 | Eingeleitet | Stephens | Overweight |
| 2024-03-28 | Eingeleitet | Piper Sandler | Overweight |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-10-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-07 | Eingeleitet | Oppenheimer | Outperform |
| 2019-05-28 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-05-28 | Eingeleitet | Cowen | Outperform |
| 2019-05-28 | Eingeleitet | JP Morgan | Overweight |
| 2019-05-28 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Transmedics Group Inc Aktie (TMDX) Neueste Nachrichten
TransMedics Group Inc (TMDX) Shares Fall 3.3% -- What GF Score o - GuruFocus
Diversify Advisory Services LLC Purchases Shares of 15,872 TransMedics Group, Inc. $TMDX - MarketBeat
TransMedics (TMDX) Outlook: Rises 3.62% to $93.97 on the Day; Trading Range: $89.27 and $98.67 Define the Nearby Reference LevelsSector Neutral Pair - Vinanet
Rosen Law Firm investigates TransMedics Group f... - Pluang
Summit Creek Advisors LLC Takes $1.77 Million Position in TransMedics Group, Inc. $TMDX - MarketBeat
Q1 2026 Transmedics Group Inc Earnings Call Transcript - GuruFocus
Transmedics Group Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Q4 2025 Transmedics Group Inc Earnings Call Transcript - GuruFocus
TransMedics Targets $2B Opportunity With Kidney Push, European Expansion - Yahoo Finance
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of ... - Caledonian Record
TransMedics Group, Inc. Investor News: Rosen Law Firm - GlobeNewswire
TransMedics (TMDX) director gifts 18,000 shares - Stock Titan
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc.TMDX - Business Wire
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Morningstar
TransMedics Group, Inc. (TMDX) Stock Analysis: Unveiling Growth Potential with a 9.84% Upside - DirectorsTalk Interviews
TransMedics Group, Inc. $TMDX Shares Sold by Royal Bank of Canada - MarketBeat
Law firm investigates TransMedics officers for possible shareholder duty breaches - Pluang
TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
ETFs Investing in TransMedics Group, Inc. Stocks - TradingView
ChronicCareIQ Appoints Tom Visotsky as Chief Revenue Officer - AOL.com
Transmedics Group Stock Price Forecast. Should You Buy TMDX? - StockInvest.us
TransMedics (TMDX) Q2 2026 Earnings Call Transcript - AOL.com
symbol__ Stock Quote Price and Forecast - CNN
(TMDX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Wasatch Advisors LP Has $20.49 Million Stock Position in TransMedics Group, Inc. $TMDX - MarketBeat
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc.TMDX - Sahm
TMDX: Strong growth, new kidney program, and global expansion set stage for multi-billion revenue - TradingView
TransMedics Group, Inc. (TMDX) Stock Analysis: Healthcare Innovations with a 15.99% Upside Potential - DirectorsTalk Interviews
Why TransMedics Stock Is Sinking Today - AOL.com
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Microvast Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX - GlobeNewswire Inc.
TransMedics Group Inc (TMDX) Stock Up 4.9% and Still Undervalued -- GF Score: 70/100 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
TransMedics: Margins Down, Concentration Up, Trials Delayed - Seeking Alpha
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc.TMDX - Sahm
Q2 2026 Transmedics Group Inc Earnings Call Transcript - GuruFocus
TransMedics Group (NASDAQ:TMDX) Price Target Lowered to $77.00 at UBS Group - MarketBeat
Why TransMedics Group (TMDX) Stock Is Down Today - Quiver Quantitative
TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract - Yahoo Finance
TransMedics Group (NASDAQ:TMDX) Shares Gap Down on Disappointing Earnings - MarketBeat
TransMedics Group, Inc. Stock 12‑Month Price Target Cut to $97.3, Implies 20% Upside - TradingView
TransMedics Group, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:TMDX) 2026-08-05 - Seeking Alpha
TransMedics Group (TMDX) Stock Looks Cheap On Earnings But Full After 171% Gain - Yahoo Finance
TransMedics Group Inc (TMDX) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
TransMedics Group Q2 Earnings Call Highlights - MarketBeat
Do TransMedics’ (TMDX) New Equity Grants And UBS Coverage Reveal A Shifting Growth Playbook? - webull.com
TransMedics Group (NASDAQ:TMDX) Posts Earnings Results, Misses Expectations By $0.06 EPS - MarketBeat
TransMedics (TMDX) Reports Q2 Earnings: What Key Metrics Have to Say - finance.yahoo.com
Earnings call transcript: TransMedics Q2 2026 revenue rises, but EPS misses - Investing.com
Is TransMedics Group Inc (TMDX) Undervalued After Q2 Earnings Mi - GuruFocus
TransMedics Group Q2 Adjusted Net Income Falls, Revenue Rises - marketscreener.com
Finanzdaten der Transmedics Group Inc-Aktie (TMDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):